Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

The FDA on Tues­day re­leased an in­spec­tion re­port sent to No­vo Nordisk ear­li­er this year cit­ing qual­i­ty-re­lat­ed is­sues at a site in Kalund­borg, Den­mark, that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER